SCHEMBL5557917

SCHEMBL5557917

COc1ccc(NC(=O)CC(=O)c2cccc(-c3cccnc3)c2)c(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 3/20 0.46
TSHR P16473 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 3/20 0.43
HKDC1 Q2TB90 1/20 0.43
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
CYP17A1 P05093 1/20 0.41
CYP19A1 P11511 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
KMO O15229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5558241 0.91 CYP19A1 (0.44) ABCB1TSHRSMN1; SMN2KMT2ACYP11B1
SCHEMBL5557200 0.91 AURKA (0.47) KMT2AERCC5FEN1CYP17A1ALDH1A1
SCHEMBL5562657 0.91 ABL1 (0.47) ABCB1CYP11B1CYP11B2ABL1
SCHEMBL5563604 0.89 TEK (0.42) ABCB1CYP17A1ABL1KMO
SCHEMBL5561947 0.89 TEK (0.42) ABCB1CYP17A1ABL1KMO
SCHEMBL5562530 0.88 MAPK1 (0.42) ABCB1SMN1; SMN2POLBKMT2ACYP17A1
SCHEMBL5556993 0.88 ABCB1 (0.43) ABCB1CYP17A1ALDH1A1KMO
SCHEMBL5556638 0.87 MEN1 (0.44) ABCB1TSHRPOLBKMT2ACYP17A1
SCHEMBL5562768 0.84 HTR2C (0.46) ABCB1TSHRKMT2AMAPTMEN1
SCHEMBL5563068 0.84 GBA1 (0.41) ABCB1SMN1; SMN2CYP17A1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 ABCB1 529/4885TSHR 3676/4885SMN1; SMN2 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.